Table 1.

Immunotherapy Agents for Urothelial Carcinoma

Agent	Current Role	Mechanism	Outcomes
Intravesical BCG	Non-muscle-invasive bladder cancer	Stimulation of cellular and humoral responses	Reduces disease recurrence and progression
Atezolizumab	Systemic delivery in advanced disease	Anti-PD-L1 monoclonal antibody	23% overall response rate and 15.9-mo overall survival in cisplatin-ineligible group
Pembroluzimab	Systemic delivery in advanced disease	Monoclonal anti-PD-1 antibody	28.9% overall response in cisplatin-ineligible patients
			In neoadjuvant setting 32% pT0 disease post-cystectomy